Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
Treating actinic keratoses with Efudix® cream
Sandeep Varma
Five per cent 5-fluorouracil cream (5-FU); Efudix® (Valeant Pharmaceuticals Ltd, UK) has proven to be an effective treatment for actinic keratoses. The case study described below presents a patient’s unique perspective on the inflammation and redness associated with 5% 5- FU therapy. At the end of therapy, the patient concluded that his skin hadn’t looked so well in years and that, despite the inflammation and redness the therapy was ‘worth it’.
Dermatology in practice
2007;
15
(2): 9–10
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
J&J presents positive phase 3b results for Tremfya in plaque psoriasis
Bristol Myers Squibb shares positive phase 3b/4 results for Sotyktu in scalp psoriasis
Eli Lilly/Almirall announce long-term results for IL-13 inhibitor Ebglyss in atopic dermatitis
LEO Pharma’s Anzupgo cream granted EC approval in chronic hand eczema
UCB announces two-year data for Bimzelx in hidradenitis suppurativa
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy